Infinimmune Raises $75M To Advance Human Antibody Pipeline

Infinimmune has secured $75 million in Series A funding to propel its antibody therapeutics pipeline forward. The financing round was co-led by Regeneron Ventures and Playground Global, alongside participation from a number of new and existing investors. This infusion of capital follows significant progress in Infinimmune's discovery platform and therapeutic programs. The company aims to advance two lead candidates for atopic dermatitis, with initial first-in-human studies expected to commence in 2027.

Infinimmune's innovative Anthrobody platform screens millions of memory B cells across hundreds of targets, identifying naturally paired human antibodies with desirable therapeutic properties. Computational GLIMPSE antibody language models then guide the optimization of these candidates for improved potency, specificity, half-life, and developability.

The lead candidate, IFX-101, is a potential first-in-class monoclonal antibody for atopic dermatitis, while IFX-201 targets interleukin-13 and is being developed as a potentially best-in-class treatment option.

Atopic dermatitis, a chronic skin inflammation condition, currently has limited treatment options, with some patients experiencing suboptimal disease control. Infinimmune believes that its improved potency and dosing convenience could address these limitations. The company aims to develop antibodies with longer activity periods.

In March 2026, Infinimmune signed a multi-target antibody discovery collaboration with Merck, which includes up to $838 million in upfront and milestone payments. The partnership emphasizes Infinimmune's human-first approach to antibody discovery and therapeutic development.